Sjögren's Syndrome patient and patient research partner for rheumatic diseases.

Rebecca Anson, patient and patient research partner

Samuel Silva from the Department of Pathology at Federal University of Ceará in Fortaleza, Brazil, discusses a research paper he co-authored that was published in Oncotarget Volume 15, titled, “Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC.”

DOI - https://doi.org/10.18632/oncotarget.28660

Correspondence to - Fabio Tavora - fabio.tavora@argospatologia.com

Video interview - https://www.youtube.com/watch?v=bJO2MD8AXkY

Video transcription - https://www.oncotarget.net/2024/11/18/behind-the-study-dll3-asc1-ttf-1-ki-67-in-precision-medicine-for-sclc/

Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28660

Subscribe for free publication alerts from Oncotarget: 
https://www.oncotarget.com/subscribe/

Keywords - cancer, DLL3, pathology, biomarkers, qupath, small cell carcinoma

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget

Behind the Study: DLL3, ASC1, TTF-1 & Ki-67 in Precision Medicine for SCLC

Dr. Fabienne Hershkowitz Sikron from the Meuhedet Health Maintenance Organization (HMO) in Tel-Aviv, discusses a #research paper she co-authored that was #published in Volume 16, Issue 20 of Aging, entitled “Development and validation of an electronic frailty index in a national health maintenance organization.”

DOI - https://doi.org/10.18632/aging.206141

Corresponding Author - Fabienne Hershkowitz Sikron - fabian_hershkowitz@meuhedet.co.il

Video interview - https://www.youtube.com/watch?v=pc9_ByZ1_ew

Video transcription - https://www.aging-us.com/interviews/validating-electronic-frailty-index-in-national-health-system

Abstract

Background: Frailty constitutes a major factor that puts the elderly at risk of health and functional deterioration.

Objectives: To develop and validate an Electronic Frailty Index based on electronic data routinely collected in the HMO.

Study design and setting: A retrospective cohort of the HMO members.

Participants: 120,986 patients, aged 65 years and over at the beginning of 2023.

Predictors: A cumulative frailty index including 36 medical, functional, and social deficits.

Outcomes: One-year all-cause mortality or hospitalization.

Statistical analysis: One-year hazard ratios were estimated for composite outcome of mortality or hospitalization using multivariable hierarchical Cox regression.

Results: The mean EFI score increased with the Social Security Nursing Benefit. Compared to fit patients, mild, moderate, and severe frailty patients had 2.07, 3.35, and 4.4-fold increased risks of mortality or hospitalization, after controlling for covariates.

Conclusions: The findings showed that the Electronic Frailty Index version we created is valid in predicting mortality or hospitalization. In addition, the Electronic Frailty Index converged with an independent measurement produced by National Social Security.

Sign up for free Altmetric alerts about this article - 
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206141

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, frailty, older people, electronic frailty index, electronic health record, health maintenance organization

About Aging-US

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Please visit our website at https://www.Aging-US.com​​ and connect with us:

Facebook - https://www.facebook.com/AgingUS/
X - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

MEDIA@IMPACTJOURNALS.COM

Aging (Aging-US)

Behind the Study: Validating Electronic Frailty Index in National Health System

The Light Gate welcomes guest: researcher and author, James C. Goodall
Date: December 30, 2024
Time: 5-7pm pacific / 8-10pm eastern
Episode: 088
Discussion: UFOs, advanced aircraft, Skunk Works, the UFO coverup


James C. Goodall is a published author with 27 books in print. He is a former Docent at Kitt Peak National Observatory, former Associate Curator at Pearl Harbor Aviation Museum, former Restoration Manager on the MoFs deHavilland Comet Mk 4C at The Museum of Flight, and a former Master sergeant at United States Air Force. He studied Business marketing at University of Minnesota. He is a recognized authority both on low-observable aircraft, such as the F-117, B-2A, the Lockheed ‘twins’ (F-22 and F-35) and the Lockheed Skunk Works family of Blackbirds, and the US Navy’s fleet of modern-day fast attack and ballistic missile submarines. He has been photographing and writing about ‘spooky’ military aircraft, naval ships and submarines for the past 35 years, and his last book, 75 years of the Lockheed Martin Skunk Works, was published by Osprey in 2021.

LINKS:
https://www.bloomsbury.com/us/author/james-c-goodall/
https://www.facebook.com/jim.goodall.71

THE LIGHT GATE   James C  Goodall   Researcher Author

The Light Gate welcomes guest: researcher and author, Cheryl Costa
Date: January 6, 2025. Time: 5-7pm pacific / 8-10pm eastern
Episode: 089
Discussion: UFOs, advanced aircraft, Skunk Works, the UFO coverup

Cheryl wears many hats and has done many things. She is a reverend, a Pagan Priestess, a Tibetan Yogini and a Trans-activist, a UFO columnist, a UFO researcher and author, and a novelist. During the Cold War, Cheryl served in the Air Force and the Navy as a government contractor. She is a two-service military veteran, USAF & USN, and a retired professional from the aerospace industry. As a journalist she was a UFO columnist for the Roswell Daily Record, and wrote the wildly popular UFO column,
"NewYorkSkies" for the
SyracuseNewTimes.com (2013-2019.) She holds a Bachelor of Arts degree from the State University of New York in Entertainment Writing and Production, and in 2018 was awarded the UFO Researcher of the Year by the International UFO Congress. She has authored dozens of books (many with her wife, Linda) in a variety of genres, including a series of UFO reference books providing undeniable proof that UFOs are being seen all over the world.


LINKS:
https://www.facebook.com/cheryl.costa.908
https://www.amazon.com/s?
k=cheryl+costa&i=stripbooks&crid=10UIZA6HLPH26&fbclid
=IwZXh0bgNhZW0CMTAAAR1p3Dds8ehCcJdoiyLUS5PzAw
yGbV418Br604DIZ64onJdKSTkmlkzlqM0_aem_ YH_T6A8yX
VFM6H4mUssoTg&sprefix=cheryl+costa%2Cstripbooks%2C9
3&ret-nb sb ss tb 1_12

THE LIGHT GATE - Cheryl Costa  Researcher Author

New York Times bestselling, award-winning author and educator Emily Nagoski is one of the most exceptional minds at work today on the science of sexual connection, intimacy, and arousal. She joins to discuss her remarkable career and new book, “Come Together.”

Best of Design Matters: Emily Nagoski, Ph.D.

Damon gets to talk to Quintin about his performing, teaching philosophies, new music research, coffee, black orchestral musicians and much more! There are also segments like gig alerts, educational spotlights, music news and others. 

#428 Quintin Mallette-Percussionist, Educator, Researcher and More!

Dr. Stefanie Morgan joins Dr. Robert Dudley from AgelessRx to discuss a #research paper she co-authored that was #published in Volume 17, Issue 4 of Aging, entitled “Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.”

DOI - https://doi.org/10.18632/aging.206235

Corresponding author - Stefanie L. Morgan - stefanie@agelessrx.com

Author interview - https://www.youtube.com/watch?v=2qlIiVh2OJs

Video short - https://www.youtube.com/watch?v=z5j2nyK2HZ8

Abstract

Design: This 48-week decentralized, double-blinded, randomized, placebo-controlled trial (NCT04488601) evaluated the long-term safety of intermittent low-dose rapamycin in a healthy, normative-aging human cohort. Participants received placebo, 5 mg or 10 mg compounded rapamycin weekly. The primary outcome measure was visceral adiposity (by DXA scan), secondary outcomes were blood biomarkers, and lean tissue and bone mineral content (by DXA scan). Established surveys were utilized to evaluate health and well-being. Safety was assessed through adverse events and blood biomarker monitoring.

Results: Adverse and serious adverse events were similar across all groups. Visceral adiposity did not change significantly (ηp2 = 0.001, p = 0.942), and changes in blood biomarkers remained within normal ranges. Lean tissue mass (ηp2 = 0.202, p = 0.013) and self-reported pain (ηp2 = 0.168, p = 0.015) improved significantly for women using 10 mg rapamycin. Self-reported emotional well-being (ηp2 = 0.108, p = 0.023) and general health (ηp2 = 0.166, p = 0.004) also improved for those using 5 mg rapamycin. No other significant effects were observed.

Conclusions: Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. Future work will evaluate benefits of a broader range of rapamycin doses on healthspan metrics for longevity, and will aim to more comprehensively establish efficacy.

Sign up for free Altmetric alerts about this article - 
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206235

Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts

Keywords - aging, rapamycin, geroscience, longevity, healthspan

To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at:

Facebook - https://www.facebook.com/AgingUS/
X - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Bluesky - https://bsky.app/profile/aging-us.bsky.social
Pinterest - https://www.pinterest.com/AgingUS/
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

MEDIA@IMPACTJOURNALS.COM

Behind the Study: Rapamycin’s 1-Year Impact on Healthspan—PEARL Trial Results

Jeremiah sheds light on being a choral conductor as a singer, a conductor, and a researcher.

Quantum Music: Dissecting the Modern Musician - Jeremiah Cawley (6/25/2025)

Aiden Deacon from the University of Minnesota-Twin Cities, Minneapolis, discusses a research paper he co-authored that was published in Volume 16 of Oncotarget, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.”

DOI - https://doi.org/10.18632/oncotarget.28758

Correspondence to - Justin Hwang - jhwang@umn.edu

Video interview - https://www.youtube.com/watch?v=OXKhWWU1gnY

Abstract

This study investigates the R-spondin family of genes (RSPO1/2/3/4), a group of secreted proteins that act as Wnt regulators, and their subsequent role in advanced prostate cancer (PC). When evaluating transcriptomic data from primary and metastatic PC patients, we found that alterations in RSPO2 were more prevalent than in other RSPO family members or Wnt-regulating genes APC and CTNNB1. Further, we found that RSPO2 alterations in PCs were significantly associated with worse disease-free survival. Through our in silico modeling, RSPO2 exhibited strong positive associations with genes regulating epithelial-mesenchymal transition (EMT) and double-negative prostate cancer (DNPC), but had negative correlations with androgen receptor (AR) and AR-associated genes. Furthermore, 3D modeling of RSPO2 revealed structural differences between itself and other RSPOs. In cell lines, RSPO2 overexpression caused up-regulation of EMT pathways, including EMT-regulatory transcription factors ZEB1, ZEB2, and TWIST1. Conversely, this was not observed when CTNNB1 was overexpressed in the same models. These findings highlight that, in PC, RSPO2 functions as a unique member of the R-spondin family by promoting genes and signaling pathways associated with aggressive PC, and RSPO2 amplifications are associated with poor outcomes in PC patients.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28758

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, RSPO2, prostate cancer, Wnt signaling, genomics, therapeutics

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget author interview: Aiden Deacon

Behind the Study: R-spondin Family Roles in Metastatic Prostate Cancer

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Aging-US is dedicated to advancing our understanding of the biological mechanisms that drive aging and the development of age-related diseases. Our mission is to serve as a platform for high-quality research that uncovers the cellular, molecular, and systemic processes underlying aging, and translates these insights into strategies to extend healthspan and delay the onset of chronic disease.

Read about the Aging (Aging-US) Scientific Integrity Process: https://aging-us.com/scientific-integrity

The Health Design Podcast brought to you by the Journal of Health Design(www.journalofhealthdesign.com). Features interviews with the world's leading health design experts including clinicians, designers, patients, authors and researchers. Better health by design.

Welcome to Riverwest Radio – WXRW 104.1 FM

Riverwest Radio is a nonprofit storefront community radio & podcasting platform dedicated to uplifting Milwaukee voices through locally produced content.

MISSION STATEMENT
Riverwest Radio provides a community platform for education, advocacy and creativity, as well as an outlet for marginalized and alternative voices in our neighborhood and beyond. We invite all Milwaukeeans not only to listen, but to take an active role in the production of their own show and become stewards of the station.

Design Matters by Debbie Millman features interviews with designers, artists and cultural leaders, including Lawrence Weiner, Barbara Kruger, Malcolm Gladwell, Eric Kandel, Stefan Sagmeister, John Maeda, Jonathan Hoefler and Tobias Frere-Jones, Michael Arad, Milton Glaser, Massimo Vignelli, Paula Scher, Steven Heller, Jonah Lehrer, among others.

In 2011, Design Matters received the People’s Design Award from the prestigious Cooper-Hewitt National Design Awards.

Subscribe to Design Matters for free on iTunes, where new episodes are uploaded weekly: http://itunes.apple.com/us/podcast/design-matters-debbie-millman/id328074695

The best variety in News, Sports, Esoteric talk online and over the airwaves on Earth. The new learning channel UPRNtalkradio.com

New tracks tagged #Researcher